['The expression of matrix metalloproteinases 2 (MMP-2) and 9 (MMP-9) and tissue inhibitors of matrix metalloproteinases 1 (TIMP-1) and 2 (TIMP-2) in vulvar intraepithelial neoplasia (VIN I-III) and in vulvar invasive carcinoma were evaluated.', 'A retrospective study.', 'Oulu University Hospital, Finland.', 'The study population consisted of 68 patients with vulvar neoplasia (13 VIN I, 5 VIN II, 6 VIN III and 44 squamous cell carcinomas).', 'Paraffin-embedded tissue samples were examined by immunohistochemistry.', 'MMP-2, MMP-9, TIMP-1 and TIMP-2 expression in VIN compared to vulvar carcinoma.', 'In VIN I-III MMP-2 expression was positive in 13%, MMP-9 in 13%, TIMP-1 in 50% and TIMP-2 in 17% of patients. The positive expressions in patients with vulvar carcinoma were 52% for MMP-2, 36% for MMP-9, 41% for TIMP-1 and 78% for TIMP-2.'] Is increased matrix metalloproteinases 2 and 9 and tissue inhibitor of matrix metalloproteinase 2 expression associated with progression from vulvar intraepithelial neoplasia to invasive carcinoma?